Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2017

01-04-2017 | Original Article

Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation

Authors: Joseph Ahn, Benny Liu, Taft Bhuket, Robert J. Wong

Published in: Digestive Diseases and Sciences | Issue 4/2017

Login to get access

Abstract

Background

Chronic hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC) and need for liver transplantation (LT). It is unclear if HCV-related LT outcomes vary by race/ethnicity.

Aims

We aim to evaluate ethnic disparities specifically among patients with chronic HCV in the USA.

Methods

Using data from the United Network for Organ Sharing 2003–2013 LT registry, we evaluated race/ethnicity-specific disparities in LT waitlist survival and probability of receiving LT among chronic HCV patients listed for LT.

Results

Among 43,478 HCV patients listed for LT (70.0% non-Hispanic white, 10.8% black, 16.3% Hispanic, 2.9% Asian), HCV-related LT waitlist registrations increased by 21.5% from 2003 to 2013. During this period, the proportion of HCV patients with HCC increased by 237%, and in 2013, HCV patients with HCC accounted for 33.0% of HCV-related waitlist registrations. When stratified by race/ethnicity, Hispanics with HCV had significantly lower waitlist mortality (OR 0.83; 95% CI 0.74–0.94; p < 0.01) compared to non-Hispanic whites, but no significant differences were seen among blacks and Asians. Furthermore, compared to non-Hispanic whites, Hispanics were significantly less likely to receive LT (OR 0.58; 95% CI 0.53–0.62; p < 0.001), but no differences were seen among blacks or Asians.

Conclusion

Among patients with chronic HCV in the USA, the MELD score has reduced race/ethnicity-specific disparities in waitlist mortality. However, Hispanic HCV patients had significantly better waitlist survival and lower probability of receiving LT, possibly reflecting slower disease progression compared to non-Hispanic whites with chronic HCV.
Literature
1.
go back to reference Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology (Baltimore, Md.). 2005;41:1407–1432.CrossRef Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology (Baltimore, Md.). 2005;41:1407–1432.CrossRef
2.
go back to reference Organ Procurement and Transplantation Network. Health Resources and Services Administration, HHS. Final rule Federal register. 1999;64:56650–56661. Organ Procurement and Transplantation Network. Health Resources and Services Administration, HHS. Final rule Federal register. 1999;64:56650–56661.
3.
go back to reference Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transplant. 2004;10:834–841.CrossRef Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transplant. 2004;10:834–841.CrossRef
4.
go back to reference Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. Jama. 2004;291:1871–1874.CrossRefPubMed Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. Jama. 2004;291:1871–1874.CrossRefPubMed
5.
go back to reference Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. Jama. 2008;300:2371–2378.CrossRefPubMedPubMedCentral Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. Jama. 2008;300:2371–2378.CrossRefPubMedPubMedCentral
6.
go back to reference Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the surveillance, epidemiology, and end results registry. Liver Transplant. 2014;20:528–535.CrossRef Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the surveillance, epidemiology, and end results registry. Liver Transplant. 2014;20:528–535.CrossRef
7.
go back to reference Wong RJ, Ahmed A. Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database. Clin Transplant. 2014;28:755–761.CrossRefPubMed Wong RJ, Ahmed A. Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database. Clin Transplant. 2014;28:755–761.CrossRefPubMed
8.
go back to reference Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology (Baltimore, Md.). 2014;59:2188–2195.CrossRef Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology (Baltimore, Md.). 2014;59:2188–2195.CrossRef
9.
go back to reference Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMed
10.
go back to reference Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006;10:919–940.CrossRefPubMed Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006;10:919–940.CrossRefPubMed
12.
go back to reference Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology (Baltimore, Md.). 1997;26:34S–38S.CrossRef Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology (Baltimore, Md.). 1997;26:34S–38S.CrossRef
13.
go back to reference Yan M, Ha J, Aguilar M, et al. Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. J Hepatol. 2016;64:326–332.CrossRefPubMed Yan M, Ha J, Aguilar M, et al. Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. J Hepatol. 2016;64:326–332.CrossRefPubMed
14.
go back to reference Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology (Baltimore, Md.). 2016;64:1442–1450.CrossRef Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology (Baltimore, Md.). 2016;64:1442–1450.CrossRef
15.
go back to reference Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014;161:170–180.CrossRefPubMedPubMedCentral Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014;161:170–180.CrossRefPubMedPubMedCentral
16.
go back to reference Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol. 2016;50:423–430.CrossRefPubMed Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol. 2016;50:423–430.CrossRefPubMed
17.
go back to reference Alavi M, Law MG, Grebely J, et al. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study. J Hepatol. 2016;65:879–887.CrossRefPubMed Alavi M, Law MG, Grebely J, et al. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study. J Hepatol. 2016;65:879–887.CrossRefPubMed
18.
go back to reference Thein HH, Walter SR, Gidding HF, et al. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992–2007. J Viral Hepatitis. 2011;18:e232–e241.CrossRef Thein HH, Walter SR, Gidding HF, et al. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992–2007. J Viral Hepatitis. 2011;18:e232–e241.CrossRef
19.
go back to reference Heimbach JK, Hirose R, Stock PG, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology (Baltimore, Md.). 2015;61:1643–1650.CrossRef Heimbach JK, Hirose R, Stock PG, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology (Baltimore, Md.). 2015;61:1643–1650.CrossRef
20.
go back to reference O’Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol. 2011;9:700–704 e701. O’Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol. 2011;9:700–704 e701.
21.
go back to reference Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002–2012 United Network for Organ Sharing data. Clin Transplant. 2014;28:713–721.CrossRefPubMed Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002–2012 United Network for Organ Sharing data. Clin Transplant. 2014;28:713–721.CrossRefPubMed
Metadata
Title
Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation
Authors
Joseph Ahn
Benny Liu
Taft Bhuket
Robert J. Wong
Publication date
01-04-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4469-2

Other articles of this Issue 4/2017

Digestive Diseases and Sciences 4/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.